Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice

Nora Khiar-Fernández, Debora Zian, Henar Vázquez-Villa, R. Fernando Martínez, Andrea Escobar-Peña, Román Foronda-Sainz, Manisha Ray, Maria Puigdomenech-Poch, Giovanni Cincilla, Melchor Sánchez-Martínez, Yasuyuki Kihara, Jerold Chun, Rubèn López-Vales, María L. López-Rodríguez*, Silvia Ortega-Gutiérrez

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Spinal cord injuries (SCIs) irreversibly disrupt spinal connectivity, leading to permanent neurological disabilities. Current medical treatments for reducing the secondary damage that follows the initial injury are limited to surgical decompression and anti-inflammatory drugs, so there is a pressing need for new therapeutic strategies. Inhibition of the type 2 lysophosphatidic acid receptor (LPA2) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. Toward validating this receptor as a target in SCI, we have developed a new series of LPA2antagonists, among which compound 54 (UCM-14216) stands out as a potent and selective LPA2receptor antagonist (Emax= 90%, IC50= 1.9 μM, KD= 1.3 nM; inactive at LPA1,3-6receptors). This compound shows efficacy in an in vivo mouse model of SCI in an LPA2-dependent manner, confirming the potential of LPA2inhibition for providing a new alternative for treating SCI.

Original languageEnglish
Pages (from-to)10956-10974
Number of pages19
JournalJournal of Medicinal Chemistry
Volume65
Issue number16
DOIs
Publication statusPublished - 10 Aug 2022

Keywords

  • Animals
  • Mice
  • Receptors, Lysophosphatidic Acid/antagonists & inhibitors
  • Spinal Cord
  • Spinal Cord Injuries/drug therapy

Fingerprint

Dive into the research topics of 'Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice'. Together they form a unique fingerprint.

Cite this